{"keywords":["checkpoint inhibitors","immune-mediated","ipilimumab","melanoma","neutropenia"],"genes":["human monoclonal IgG1 antibody","CTLA-4","anti-thymocyte globulin"],"organisms":["9606"],"publicationTypes":["Journal Article"],"abstract":"Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of advanced melanoma. The most common adverse events associated with ipilimumab are immune-related. Severe hematological toxicity is rare. We report a case of severe neutropenia following ipilimumab therapy that fully resolved after the administration of prednisone, cyclosporine, and anti-thymocyte globulin therapies. ","title":"Ipilimumab-Induced Neutropenia in Melanoma.","pubmedId":"27570779"}